HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Novel techniques may provide ‘incredible’ benefits to enhance CAR T-cell therapy Josh Friedman
-
- Findings highlight ‘critical importance’ of infectious complications after CAR-T Jennifer Byrne
- As influence increases, digital opinion leaders need ‘guidelines and guardrails’ Mark Leiser
- Blood cancer does not accelerate cognitive decline among older adults Matthew Shinkle
- Cincinnati Children’s again ranked best hospital for pediatric cancer Mark Leiser
- Combination prolongs PFS in intermediate-stage hepatocellular carcinoma Mark Leiser
- Datopotamab deruxtecan fails to extend OS vs. chemotherapy in advanced breast cancer Matthew Shinkle
- Enrollment of trial assessing triplet for leukemia halted after ‘unexpected’ outcome Mark Leiser
- FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy Mark Leiser
-
- FDA approves isatuximab-irfc combination for certain adults with multiple myeloma
- FDA approves novel immunotherapy for cutaneous T-cell lymphoma Mark Leiser
- ‘Intentional’ efforts needed to address DEI challenges in cancer care Jennifer Byrne
- Long-term data support pembrolizumab as ‘a standard of care’ in advanced melanoma Josh Friedman
- Lung cancer trial halted due to lack of survival benefit, higher toxicity Mark Leiser
- Multifaceted strategy needed to combat cancer misinformation on social media Mark Leiser
- Nivolumab plus ipilimumab offers ‘potential for cure’ in advanced melanoma Josh Friedman
- Obesity associated with longer survival in immunotherapy-treated head, neck cancer Matthew Shinkle
-
- Olanzapine improves nausea, quality of life more effectively than prochlorperazine Josh Friedman
- Patritumab deruxtecan extends PFS vs. chemotherapy in advanced non-small cell lung cancer Matthew Shinkle
- Pembrolizumab regimen extends OS in triple-negative breast cancer Mark Leiser
- Pharmacy specialist, BRCA2 carrier: ‘Genetic testing saved my life’ Jennifer Byrne
- Phase 3 trials of pembrolizumab for lung cancer, skin cancer halted due to lack of efficacy Mark Leiser
- Positive trial of ponsegromab may signal ‘start of a revolution’ for cancer cachexia Josh Friedman
- Radium-223 helps delay radiographic progression in metastatic prostate cancer Mark Leiser
- Retifanlimab regimen improves outcomes in advanced anal cancer Mark Leiser
-
- Serious cardiovascular events rare after CAR T-cell therapy Josh Friedman
- ‘Sobering’ data show excessive cannabis use increases risk for head and neck cancer Josh Friedman
- Study reveals ‘multifaceted consequences’ of cisplatin shortage Josh Friedman
- Tafasitamab regimen improves PFS in advanced follicular lymphoma Mark Leiser
- Trial of vaccine plus pembrolizumab for head/neck cancer misses endpoint Matthew Shinkle
- ‘You have the power’: Social media can support equity in oncology Mark Leiser
- ASTRO members receive fellows designation Mark Leiser
- ASH to honor quality improvement champions Mark Leiser
-
- City of Hope Orange County appoints executive medical director of colorectal surgery Mark Leiser
- Dana-Farber president announces intention to step down, successor named Mark Leiser
- Fox Chase Cancer Center appoints division chief of surgical oncology Mark Leiser